Since PD-1 and/or PD-L1 overexpression occurs in various tumors, the block of this axis by anti-PD1/PD-L1 mAbs has proven to be effective in several cancer types, including hematologic malignancies [149]. Here, CD274 is linked to hematologic disorder.